Clinical trials: Primary Open-Angle Glaucoma (POAG)
- Condition Primary Open-Angle Glaucoma (POAG)
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma
Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes
This clinical trial compares two implantable devices intended to lower the pressure inside the eye of glaucoma patients.
- Conditions
- Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Pigmentary Glaucoma
- Trial name
- COMPARE (NCT02023242)
- Testing
- Hydrus Microstent, iStent Trabecular Micro Bypass
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Ivantis, Inc.
Primary Open-angle Glaucoma and Ocular Hypertension
DE-117 Spectrum 5 Study
Santen will evaluate the intraocular pressure (IOP) lowering effect and efficacy of DE-117 ophthalmic solution 0.002% in latanoprost low/non-responder subjects diagnosed with POAG or OHT
- Trial name
- NCT03697811
- Testing
- DE-117 Ophthalmic Solution
- Where
- 32 sites in United States
- Volunteers
- 107 people
- Sponsor
- Santen Inc.
Primary Open Angle Glaucoma
InnFocus MicroShunt Versus Trabeculectomy Study
Assess the safety and effectiveness of the InnFocus MicroShunt when used to lower intraocular pressure (IOP) in subjects with primary open angle glaucoma where the IOP is not controlled when using maximum tolerated glaucoma…
- Trial name
- IMS (NCT01881425)
- Testing
- Glaucoma Surgery, InnFocus MicroShunt
- Where
- 29 sites in United States, France and 4 more
- Volunteers
- 732 people
- Sponsor
- InnFocus Inc.
Open-Angle Glaucoma, Ocular Hypertension
Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension
The purpose of this study is to evaluate the safety (in the eye and throughout the body) and effectiveness of nebivolol (0.5 and 1 percent) and timolol (0.5 percent) eye drop suspensions.
- Trial name
- NCT04910100
- Testing
- Nebivolol Ophthalmic Suspension 1 Percent, Nebivolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Suspension 0.5 Percent
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- Betaliq, Inc.
Open Angle Glaucoma, Ocular Hypertension
DE-111 Against Timolol Ophthalmic Solution 0.5%
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Timolol ophthalmic solution 0.5%, in IOP(intraocular pressure ) -lowering effect in primary open-angle glaucoma or ocular hypertension patients, in a…
- Trial name
- NCT01342094
- Testing
- DE-111 ophthalmic solution, Timolol ophthalmic solution 0.5%
- Where
- Japan
- Volunteers
- 166 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open Angle Glaucoma, Ocular Hypertension
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
Aim: To demonstrate the non-inferiority of the PRO-067 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus GAAP Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle…
- Trial name
- COMPLIANCE (NCT02801617)
- Testing
- PRO-067, GAAP Ofteno®
- Where
- Mexico
- Volunteers
- 116 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Primary Open Angle Glaucoma (POAG)
A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial
The purpose of this study is to evaluate the long-term safety of the CyPass Micro-Stent in subjects who completed Study Protocol TMI-09-01, COMPASS Trial.
- Trial name
- COMPASS-XT (NCT02700984)
- Testing
- CyPass Micro-Stent, Cataract Surgery
- Where
- 22 sites in United States
- Volunteers
- 282 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01217606
- Testing
- bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy), Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
- Where
- Brazil
- Volunteers
- 185 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
An observational study comparing changing from an IOP-lowering treatment to a bimatoprost-containing IOP treatment in primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
- Trial name
- NCT01646151
- Testing
- Bimatoprost
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 2,580 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma, Cataract
Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent
The purpose of this study is to assess long-term (10 years post-CyPass implantation) status of the corneal endothelium in subjects who were implanted with the CyPass Micro-Stent in the COMPASS trial.
- Trial name
- COMPASS XXT (NCT04629521)
- Testing
- CyPass Micro-Stent, Cataract Surgery
- Where
- 12 sites in United States
- Volunteers
- 54 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.
- Trial name
- LOTUSDI (NCT02020512)
- Testing
- 0.03% Bimatoprost
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Allergan
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
The study will evaluate patients diagnosed with POAG or OHT who are switched to GANFORT® UD (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in accordance with physician standard clinical…
- Trial name
- NCT01999348
- Testing
- Fixed Combination Bimatoprost and Timolol
- Where
- Germany
- Volunteers
- 1,553 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma or Ocular Hypertension
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo
- Trial name
- NCT03233308
- Testing
- Netarsudil Ophthalmic Solution 0.02%
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aerie Pharmaceuticals
Primary Open Angle Glaucoma (POAG)
Study of CyPass Implantation In Patients With Open Angle Glaucoma Refractory to Single or Multi-agent Topical Therapy
The purpose of this study is to evaluate the safety and effectiveness of CyPass implantation as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) who have failed at…
- Trial name
- DUETTE (NCT01166659)
- Testing
- CyPass Micro-Stent
- Volunteers
- 48 people
- Sponsor
- Transcend Medical, Inc.
Glaucoma and Ocular Hypertension
Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma
This is a multiple cohort study that will evaluate the safety and efficacy of ENV515 travoprost XR in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02371746
- Testing
- ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR
- Where
- 14 sites in United States
- Volunteers
- 41 people
- Sponsor
- Envisia Therapeutics
Glaucoma, Open-Angle, Ocular Hypertension
An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
This study is a prospective, observational study of changing from any IOP-lowering treatment to a prostaglandin analogue-containing IOP-lowering medication for patients with Primary Open Angle Glaucoma (POAG) or Ocular…
- Trial name
- NCT01735214
- Testing
- Prostaglandin Analogue -Containing IOP-Lowering Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 358 people
- Sponsor
- Allergan
Ocular Hypertension, Glaucoma
Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or…
- Trial name
- NCT00809848
- Testing
- AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Allergan
Primary Open-angle Glaucoma
Long-term Safety and Performance of the ARGOS-IO Intraocular Pressure Sensor System in Subjects With Primary Open Angle Glaucoma (POAG)
The purpose of this study is to evaluate the long-term safety and performance of the ARGOS-IO system in patients with Primary Open Angle Glaucoma (POAG)
- Trial name
- NCT03651336
- Testing
- ARGOS-IO Sensor Pressure System
- Where
- 4 sites in Germany
- Volunteers
- 16 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Glaucoma, Open-Angle, Ocular Hypertension
Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.
Phase IV randomized, double blind, multicenter, parallel group clinical study to evaluate the efficacy of the combined use of Krytantek Ofteno PF® and Gaap Ofteno PF®, both applied every 12 hours, versus the use of Eliptic Ofteno…
- Trial name
- PRO-122 (NCT04702789)
- Testing
- Dorzolamide-timolol-brimonidine and latanoprost, Dorzolamide-timolol and latanoprost
- Where
- Mexico
- Volunteers
- 28 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Primary Open Angle Glaucoma, Ocular Hypertension
Study of LL-BMT1 in Patients With Elevated Intraocular Pressure
This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.
- Trial name
- NCT04747808
- Testing
- LL-BMT1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- MediPrint Ophthalmics, Inc.